Original language | English |
---|---|
Number of pages | 1 |
Journal | Journal of Clinical Oncology |
Volume | 32 |
Issue number | 15 |
DOIs | |
Publication status | Published - 20 May 2014 |
Externally published | Yes |
Event | 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States Duration: 30 May 2014 → 3 Jun 2014 |
A phase 1b study of the anticancer stem cell agent demcizumab (DEM), pemetrexed (PEM), and carboplatin (CARBO) in pts with first-line nonsquaamous NSCLC
Mark James McKeage, Dusan Kotasek, Ben Markman, Manuel Hidalgo, Michael Millward, Michael B. Jameson, Dean Laurence Harris, Robert J. Stagg, Jakob Dupont, Brett Gordon Maxwell Hughes
Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review
2
Citations
(Web of Science)